DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans

• Published in: Drug discovery today Vol. 21; no. 4; pp. 648 - 653
• Main Authors: Chen, Minjun, Suzuki, Ayako, Thakkar, Shraddha, Yu, Ke, Hu, Chuchu, Tong, Weida
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2016
• Subjects: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations - classification; Risk
• ISSN: 1359-6446; 1878-5832; 1878-5832
• DOI: 10.1016/j.drudis.2016.02.015

•DILIrank contains the largest number of drugs (N=1036) ranked by their risk for causing DILI.•The existing drug labeling-based DILI annotation was enhanced by weighing evidence of causality.•Drugs were classified as verified vMost-, vLess-, vNo-DILI-concern, leaving out terminology ‘Ambiguous DILI-concern’ drugs.•DILIrank is invaluable for the development of predictive models using emerging technologies. High-throughput methods are powerful tools to develop predictive models for assessing drug-induced liver injury (DILI). However, the development of predictive models requires a drug reference list with an accurate annotation of DILI risk in humans. We previously developed a DILI annotation schema based on information curated from the US Food and Drug Administration (FDA)-approved drug labeling for 287 drugs. In this article, we refine the schema by weighing the evidence of causality (i.e., a verification process to evaluate a drug as the cause of DILI) and generate a data set that ranks the DILI risk (DILIrank) in humans for 1036 FDA-approved drugs, providing the largest annotated data set of such drugs in the public domain.